国产长春瑞滨联合顺铂治疗初治晚期非小细胞肺癌

目的评价国产长春瑞滨与顺铂联合化疗对初治非小细胞肺癌的近期疗效和毒性反应。方法63例患者接受化疗：NVB25mg／m^2，d1，d3，静脉滴注，CDDP 30mg／m^2，d2-d4，静脉滴注，28d为1个周期，对疗效及毒性反应进行评价。结果全部63例进行了毒性评价，因1例完成1个周期化疗故62例化疗2个周期以上者进行了疗效评价：完全缓解1．6％（1／62），部分缓解41．9％（26／62），疾病稳定33．9％（21／62），疾病进展22．2％（14／62），总有效率（CR＋PR）43．5％（27／62）。中位生存期为10.8个月。主要毒性反应为白细胞减少症、恶心呕吐、乏力、外周静脉炎，发生率分别为95．2％（60／63）、92．6％（58／63）、63．5％（40／63），49．2％（31／63），Ⅲ／Ⅳ级白细胞减少症、恶心、呕吐分别为50．8％（32／63）、63％（4／63），乏力、外周静脉炎无Ⅲ／Ⅳ级毒性。结论国产长春瑞滨联合顺铂方案（NP）有较好的近期疗效，毒性反应可耐受，可作为初治晚期非小细胞肺癌的一线治疗。

Clinical Study of Vinorelbine Combined with Cisplatin in Treatment of Untreated Advanced Non-Small Cell Lung Cancer

Objective To evaluate the therapeutic effects and side effects of vinorelbine and cisplatin in the treatment of untreated advanced non-small cell lung cancer. Methods 63 patients with untreated advanced NSCLC accepted chemotherapy： vinorelbine 25 mg/m^2 d1,d8, cisplatin 30mg/m^2, d2-d4, repeated every 28 days. The therapeutic effects and side effects were evaluated. Results Side effects were evaluated in all 63 patients and therapeutic effects were evaluated in 62 patients who at least received 2 cycle chemotherapy. Complete response rate, partial response rate, stable disease rate and progressive disease rate were 1.6% （1/62）, 41.9%（26/62）, 33.9%（21/62）, 22.2%（14/62） respectively. Total response rate was 43.5%（27/62）. The median survival time was 10.8 months. The main side effects were leucopenia, nausea and vomitting,fatigue and peripheral phlebitis. Incidence rates were 95.2% （60/63）, 92.6% （58/63）, 63.5%（40/63 ）and 49.2% （31/63 ）, respectively. Grade Ⅲ/Ⅳ of leucopenia, nausea and vomitting were 50.8%（32/63） and 6.3%（4/63）, respectively. There were no grade Ⅲ/Ⅳ fatigue and peripheral phlebitis. Conclusion The chemotherapy regimen of vinorelbine combined with cisplatin（NP） results in good short-term therapeutic effects and side effects are tolerable. It can be used as first-line chemotherapy regimen in untreated advanced NSCLC.